The presentation will be accessible via a live stream on the company’s website, where supporting slides will be published shortly before the call commences. Participants can join the discussion using dedicated dial-in lines, including +46 8 5051 0031 for Sweden, +44 203 059 58 63 for the United Kingdom, and +1 631 570 56 13 for the United States.

Sobi, which reported 28 billion SEK in revenue for the 2025 fiscal year, focuses on rare disease therapies and employs approximately 2,000 staff members globally. The company’s shares are traded on Nasdaq Stockholm under the ticker SOBI. Further inquiries regarding the event may be directed to Gerard Tobin, Head of Investor Relations.